Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
27 avr. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
23 avr. 2023 18h05 HE
|
Apellis Pharmaceuticals, Inc.
Showed visual function and quality-of-life benefits in patients with extrafoveal lesionsSlowed the loss of retinal pigmented epithelial and photoreceptor cells, both of which are required for visual...
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
21 avr. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024 WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) --...
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
17 avr. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
GA is an advanced form of age-related macular degeneration (AMD) and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 avr. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 mars 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
01 mars 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
27 févr. 2023 17h19 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its...
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
22 févr. 2023 21h48 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its...
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
22 févr. 2023 07h22 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an...